Corbus Pharmaceuticals Announces Presentations at the New York Academy of Sciences Webinar on Targeting the Endocannabinoid System to Treat Human Diseases Corbus Pharmaceuticals Holdings, Inc. Norwood, Massachusetts, UNITED STATES
Presentations about compounds in Corbus’ pipeline will highlight mechanistic studies of lenabasum, a CB2 agonist, and preclinical data from CB2 agonist oncology program and CB1 inverse agonist metabolism program
Norwood, MA, Jan. 20, 2021 (GLOBE NEWSWIRE) Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced it will participate in the New York Academy of Sciences’
webinar on January 27, 2021 on the endocannabinoid system as a target for therapeutic agents.
Published: Dec 16, 2020 By Joseph Constance
A healthy immune system defends the body against disease and other conditions. However, if the immune system malfunctions, it can attack healthy cells, tissues and organs. Autoimmune disease impacts different parts of the body, weakening functionality. It may be life-threatening.
Researchers are aware of more than
80 diseases that occur when the immune system attacks the body’s own organs, tissues and cells. The more common autoimmune diseases include type 1 diabetes, rheumatoid arthritis, systemic lupus erythematosus and inflammatory bowel disease.
Autoimmune diseases affect more than
24 million people in the U.S. On top of this, another 8 million carry auto-antibodies, blood molecules that indicate a person’s chance of developing an autoimmune disease. The cause of many of the diseases is unknown.